A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
DRUG

Fostamatinib disodium

Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.

Trial Locations (37)

1140

Hanusch-Krankenhaus, Vienna

1431

University Multiprofile Hospital for Active Treatment Sv. Ivan Rilski EAD, Varna, Clinic of Clinical Haematology, Sofia

1756

Specialized Hospital for Active Treatment of Hematological Disease EAD,, Sofia

3004

The Alfred Hospital, Melbourne

4201

Princess Alexandra Hospital - Cancer Trials Unit, Brisbane

5021

Haukeland University Hospital, Bergen

5800

"University Multiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Clinic of Medical oncology", Pleven

9100

AZ Nikolaas, Sint-Niklaas

20007

Lombardi Comprehensive Cancer Center, Washington D.C.

20122

Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico di Milano - UO Ematologia, Milan

21000

Clinical Centre of Vojvodina, Clinic for Hematology, Novi Sad

21205

John Hopkins Bayview Medical Center, Baltimore

28100

"SCDU Ematologia AOU Maggiore della Carità", Novara

33603

CHU de Bordeaux - GH Sud- Hôpital Haut Lévêque Service Médecine Interne et Maladies Infectieuses, Pessac

45147

Universitätsklinikum Essen, Essen

49102

City Clinical Hospital № 4, Hematology Center, Dnipro

70852

Fakultni nemocnice Ostrava Klinika hematoonkologie, Ostrava

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

90033

University of Southern California - Janice and Robert Hall Clinical Trials Biospecimen Laboratory, Los Angeles

90502

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance

98109

University of Washington, Seattle

98506

American Oncology Network Vista Oncology Division, Olympia

125167

National Research Center for Hematology, Moscow

210037

Vitebsk Regional Clinical Hospital, Vitebsk

210603

Vitebsk Regional Clinical Oncology Dispensary, Vitebsk

354057

State Budgetary Healthcare Institution Oncology Dispensary No. 2 of the Ministry of Health of the Krasnodar Territory, Sochi

02114

Massachusetts General Hospital, Boston

A-1090

Universitätsklinik f. Innere Medizin I - Klin. Abt. f. Hämatologie u. Hämostaseologie, Vienna

625 00

Fakultni nemocnice Brno Interni hematologicka a onkologicka klinika, Brno

0186

LTD Multiprofile Clinic Consilium Medulla, Tbilisi

M. Zodelava Hematology Centre, Tbilisi, Tbilisi

Unknown

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, UO Ematologia, Milan

Academisch Medisch Centrum, Amsterdam

08035

Hospital Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

04112

Kyiv City Clinical Hospital №9, hematology department №1, Kyiv

L7 8XP

Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool

Sponsors
All Listed Sponsors
lead

Rigel Pharmaceuticals

INDUSTRY

NCT04138927 - A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Biotech Hunter | Biotech Hunter